Implantable Cardioverter Defibrillator Use in Males with Duchenne Muscular Dystrophy and Severe Left Ventricular Dysfunction
- 1 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pediatric Cardiology
- Vol. 41 (5), 925-931
- https://doi.org/10.1007/s00246-020-02336-9
Abstract
Duchenne muscular dystrophy (DMD) is characterized by myocardial fibrosis and left ventricular (LV) dysfunction. Implantable cardioverter defibrillator (ICD) use has not been characterized in this population but is considered for symptomatic patients with severe LV dysfunction (SLVD) receiving guideline-directed medical therapy (GDMT). We evaluated ICD utilization and efficacy in patients with DMD. Retrospective cohort study of DMD patients from 17 centers across North America between January 2, 2005 and December 31, 2015. ICD use and its effect on survival were evaluated in patients with SLVD defined as ejection fraction (EF) < 35% and/ or shortening fraction (SF) < 16% on final echocardiogram. SLVD was present in 57/436 (13.1%) patients, of which 12 (21.1%) died during the study period. Of these 12, (mean EF 20.9 +/- 6.2% and SF 13.7 +/- 7.2%), 8 received GDMT, 5 received steroids, and none received an ICD. ICDs were placed in 9/57 (15.8%) patients with SLVD (mean EF 31.2 +/- 8.5% and SF 10.3 +/- 4.9%) at a mean age of 20.4 +/- 6.3 years; 8/9 received GDMT, 7 received steroids, and all were alive at study end; mean ICD duration was 36.1 +/- 26.2 months. Nine ICDs were implanted at six different institutions, associated with two appropriate shocks for ventricular tachycardia in two patients, no inappropriate shocks, and one lead fracture. ICD use may be associated with improved survival and minimal complications in DMD cardiomyopathy with SLVD. However, inconsistent GDMT utilization may be a significant confounder. Future studies should define optimal indications for ICD implantation in patients with DMD cardiomyopathy.This publication has 31 references indexed in Scilit:
- Dystrophin-Deficient CardiomyopathyJournal of the American College of Cardiology, 2016
- Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011Annals of Physical and Rehabilitation Medicine, 2013
- Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeuticsHeart Failure Reviews, 2009
- Steroid Therapy and Cardiac Function in Duchenne Muscular DystrophyPediatric Cardiology, 2005
- Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophyJournal of the American College of Cardiology, 2005
- Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophyThe American Journal of Cardiology, 2003
- Effect of Carvedilol on Survival in Severe Chronic Heart FailureThe New England Journal of Medicine, 2001
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureThe New England Journal of Medicine, 1999
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureThe New England Journal of Medicine, 1991
- The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophyInternational Journal of Cardiology, 1990